Developer site: The content shown here is test data.

Health Dictionary AI Health Chat Find an Online Doctor
A serene Zen garden with raked sand and smooth stones, symbolising clarity and calm

Health Dictionary

Back to skin conditions

Parkinson's disease history and symptoms

Introduction

Overview

Overview

Common symptoms of Parkinson disease includes: Tremor, rigidity, bradykinesia, Cognitive dysfunction and dementia, psychosis and hallucinations, mood disorders including depression, anxiety, and apathy/abulia, sleep disturbances, fatigue, olfactory dysfunction, pain and autonomic dysfunction.

History and Symptoms

History and Symptoms

history

Common symptoms

Common symptoms

The main clinical manifestations of Parkinson disease include tremor, rigidity and bradykinesia. Later in the course of the disease patient can have postural instability.[15][2][2] Some studies suggest that there can be three clinical subtypes for Parkinson disease: Tremor dominant, akinetic-rigid and postural instability and gait difficulty[16][17] but other studies demonstrate that clinical course of the disease can be variable and this subtypes can switch to each other through time.[17][18]

Motor symptoms

  • Tremor: Tremor is the most common symptom in Parkinson disease and can be the presenting sign in 70 to 80 percent of patients.[19][1] This symptom starts unilaterally mostly in hand and then progress to the other side of the body. It can also involve legs, jaw, lips and tongue.[20][21][22] PD tremor frequency is 3 to 7 Hz.[20] There is a symptom called re-emergent tremor in some of the PD patients. It manifests by postural tremor that starts after several seconds and can make it difficult to differentiate PD from essential tremor.[23][24]
  • Rigidity: Rigidity in PD in very common and can be seen in 75 to 90 percent of patients.[19][1][25] It commonly starts in the same side as the tremor. PD patients have increased resistance to passive movement of their joint and sometimes it’s known as cogwheel rigidity because of the ratchety pattern of resistance and relaxation. Some evidences suggest that superimposition of tremor on increased muscle tone creates this kind of rigidity.[26][27]
  • Bradykinesia: Bradykinesia or slowness of movement, is seen in 80 percent of PD patients.[1]
  • Postural instability: Gait and postural problems can be the main cause of disability in PD patients and commonly doesn’t response well to dopaminergic treatment.[28][29]

Nonmotor symptoms

  1. Depression: Mild to moderate depression is very common in PD and can be seen in 50 percent of PD patients.[45][46][47] these patients can present with anhedonia, sadness, guilt and feeling of worthlessness.[48]
  2. Anxiety: Anxiety, especially generalized anxiety disorder and social phobia is common in PD and can be seen in more than 30 percent of patients.[45][49] Anxiety is usually combined by depression.[50]
  3. Apathy and abulia: Apathy and abulia are characterized by lack of motivation, speech, emotional and motor function. The pathophysiology behind this symptom is involvement of frontal lobe in PD patients.[51][52]
  • Sleep disturbances: Sleep disorders is seen in 55 to 80 percent of PD patients in early or late stages of the disease.[53][54] approximately 40 percent of PD patients take medicine for sleep cause insomnia is as common as 60 percent in them.[53][54][55] the most common cause of insomnia and frequent awakening during sleep include nocturia, cramp, pain, nightmares and tremor.[55][56][57][58][59] another sleep disorder which can be seen in these patients is REM sleep behavior disorder (RBD), characterized by vigorous movement because of increased muscle tone[60][61]
  • Fatigue: The prevalence of fatigue in PD patients is 33 to 58 percent[62][63][64] it’s mostly associated with depression and excessive day time somnolence but can occur as an isolate problem too.[64][63][65]
  • Olfactory dysfunction: Deficits in odor identification and discrimination are common in PD[66] and can happen even before the motor symptoms of the disease.[67][68]
  • Pain: 46 percent of PD patients experience pain as a sense of lancinating, burning or tingling. The pain can be generalized or localized and can happen in different body areas like face, joints and genitals.[69][70][71]
References

References

  1. ↑ 1.0 1.1 1.2 1.3 Pagano G, Ferrara N, Brooks DJ, Pavese N (April 2016). “Age at onset and Parkinson disease phenotype”. Neurology. 86 (15): 1400–7. doi:10.1212/WNL.0000000000002461. PMCΒ 4831034. PMIDΒ 26865518.
  2. ↑ 2.0 2.1 2.2 Hughes AJ, Daniel SE, Kilford L, Lees AJ (March 1992). “Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases”. J. Neurol. Neurosurg. Psychiatry. 55 (3): 181–4. PMCΒ 1014720. PMIDΒ 1564476.
  3. ↑ 3.0 3.1 Noyce AJ, Bestwick JP, Silveira-Moriyama L, Hawkes CH, Giovannoni G, Lees AJ, Schrag A (December 2012). “Meta-analysis of early nonmotor features and risk factors for Parkinson disease”. Ann. Neurol. 72 (6): 893–901. doi:10.1002/ana.23687. PMCΒ 3556649. PMIDΒ 23071076.
  4. ↑ Gustafsson H, NordstrΓΆm A, NordstrΓΆm P (June 2015). “Depression and subsequent risk of Parkinson disease: A nationwide cohort study”. Neurology. 84 (24): 2422–9. doi:10.1212/WNL.0000000000001684. PMCΒ 4478031. PMIDΒ 25995056.
  5. ↑ Jiang W, Ju C, Jiang H, Zhang D (September 2014). “Dairy foods intake and risk of Parkinson’s disease: a dose-response meta-analysis of prospective cohort studies”. Eur. J. Epidemiol. 29 (9): 613–9. doi:10.1007/s10654-014-9921-4. PMIDΒ 24894826.
  6. ↑ Lv Z, Qi H, Wang L, Fan X, Han F, Wang H, Bi S (November 2014). “Vitamin D status and Parkinson’s disease: a systematic review and meta-analysis”. Neurol. Sci. 35 (11): 1723–30. doi:10.1007/s10072-014-1821-6. PMIDΒ 24847960.
  7. ↑ Jafari S, Etminan M, Aminzadeh F, Samii A (August 2013). “Head injury and risk of Parkinson disease: a systematic review and meta-analysis”. Mov. Disord. 28 (9): 1222–9. doi:10.1002/mds.25458. PMIDΒ 23609436.
  8. ↑ Scher AI, Ross GW, Sigurdsson S, Garcia M, Gudmundsson LS, SveinbjΓΆrnsdΓ³ttir S, Wagner AK, Gudnason V, Launer LJ (September 2014). “Midlife migraine and late-life parkinsonism: AGES-Reykjavik study”. Neurology. 83 (14): 1246–52. doi:10.1212/WNL.0000000000000840. PMCΒ 4180488. PMIDΒ 25230997.
  9. ↑ Savica R, Grossardt BR, Carlin JM, Icen M, Bower JH, Ahlskog JE, Maraganore DM, Steensma DP, Rocca WA (October 2009). “Anemia or low hemoglobin levels preceding Parkinson disease: a case-control study”. Neurology. 73 (17): 1381–7. doi:10.1212/WNL.0b013e3181bd80c1. PMCΒ 2769554. PMIDΒ 19858460.
  10. ↑ Petrovitch H, Ross GW, Abbott RD, Sanderson WT, Sharp DS, Tanner CM, Masaki KH, Blanchette PL, Popper JS, Foley D, Launer L, White LR (November 2002). “Plantation work and risk of Parkinson disease in a population-based longitudinal study”. Arch. Neurol. 59 (11): 1787–92. PMIDΒ 12433267.
  11. ↑ Powers KM, Smith-Weller T, Franklin GM, Longstreth WT, Swanson PD, Checkoway H (June 2003). “Parkinson’s disease risks associated with dietary iron, manganese, and other nutrient intakes”. Neurology. 60 (11): 1761–6. PMIDΒ 12796527.
  12. ↑ Hu G, Jousilahti P, Nissinen A, Antikainen R, Kivipelto M, Tuomilehto J (December 2006). “Body mass index and the risk of Parkinson disease”. Neurology. 67 (11): 1955–9. doi:10.1212/01.wnl.0000247052.18422.e5. PMIDΒ 17159100.
  13. ↑ Goldman SM, Quinlan PJ, Ross GW, Marras C, Meng C, Bhudhikanok GS, Comyns K, Korell M, Chade AR, Kasten M, Priestley B, Chou KL, Fernandez HH, Cambi F, Langston JW, Tanner CM (June 2012). “Solvent exposures and Parkinson disease risk in twins”. Ann. Neurol. 71 (6): 776–84. doi:10.1002/ana.22629. PMCΒ 3366287. PMIDΒ 22083847.
  14. ↑ Gustafsson H, Aasly J, StrΓ₯hle S, NordstrΓΆm A, NordstrΓΆm P (May 2015). “Low muscle strength in late adolescence and Parkinson disease later in life”. Neurology. 84 (18): 1862–9. doi:10.1212/WNL.0000000000001534. PMCΒ 4433465. PMIDΒ 25841033.
  15. ↑ Gelb DJ, Oliver E, Gilman S (January 1999). “Diagnostic criteria for Parkinson disease”. Arch. Neurol. 56 (1): 33–9. PMIDΒ 9923759.
  16. ↑ Marras C, Lang A (April 2013). “Parkinson’s disease subtypes: lost in translation?”. J. Neurol. Neurosurg. Psychiatry. 84 (4): 409–15. doi:10.1136/jnnp-2012-303455. PMIDΒ 22952329.
  17. ↑ 17.0 17.1 Thenganatt MA, Jankovic J (April 2014). “Parkinson disease subtypes”. JAMA Neurol. 71 (4): 499–504. doi:10.1001/jamaneurol.2013.6233. PMIDΒ 24514863.
  18. ↑ Alves G, Larsen JP, Emre M, Wentzel-Larsen T, Aarsland D (August 2006). “Changes in motor subtype and risk for incident dementia in Parkinson’s disease”. Mov. Disord. 21 (8): 1123–30. doi:10.1002/mds.20897. PMIDΒ 16637023.
  19. ↑ 19.0 19.1 Hoehn MM, Yahr MD (May 1967). “Parkinsonism: onset, progression and mortality”. Neurology. 17 (5): 427–42. PMIDΒ 6067254.
  20. ↑ 20.0 20.1 Findley LJ, Gresty MA, Halmagyi GM (June 1981). “Tremor, the cogwheel phenomenon and clonus in Parkinson’s disease”. J. Neurol. Neurosurg. Psychiatry. 44 (6): 534–46. PMCΒ 491035. PMIDΒ 7276968.
  21. ↑ Scott RM, Brody JA, Schwab RS, Cooper IS (July 1970). “Progression of unilateral tremor and rigidity in Parkinson’s disease”. Neurology. 20 (7): 710–4. PMIDΒ 5463541.
  22. ↑ Hunker CJ, Abbs JH (1990). “Uniform frequency of parkinsonian resting tremor in the lips, jaw, tongue, and index finger”. Mov. Disord. 5 (1): 71–7. doi:10.1002/mds.870050117. PMIDΒ 2296262.
  23. ↑ Jankovic J, Schwartz KS, Ondo W (November 1999). “Re-emergent tremor of Parkinson’s disease”. J. Neurol. Neurosurg. Psychiatry. 67 (5): 646–50. PMCΒ 1736624. PMIDΒ 10519872.
  24. ↑ Louis ED, Levy G, CΓ΄te LJ, Mejia H, Fahn S, Marder K (October 2001). “Clinical correlates of action tremor in Parkinson disease”. Arch. Neurol. 58 (10): 1630–4. PMIDΒ 11594921.
  25. ↑ Hughes AJ, Daniel SE, Lees AJ (1993). “The clinical features of Parkinson’s disease in 100 histologically proven cases”. Adv Neurol. 60: 595–9. PMIDΒ 8420197.
  26. ↑ Deuschl G, Bain P, Brin M (1998). “Consensus statement of the Movement Disorder Society on Tremor. Ad Hoc Scientific Committee”. Mov. Disord. 13 Suppl 3: 2–23. PMIDΒ 9827589.
  27. ↑ LANCE JW, SCHWAB RS, PETERSON EA (March 1963). “Action tremor and the cogwheel phenomenon in Parkinson’s disease”. Brain. 86: 95–110. PMIDΒ 13928399.
  28. ↑ Koller WC, Glatt S, Vetere-Overfield B, Hassanein R (April 1989). “Falls and Parkinson’s disease”. Clin Neuropharmacol. 12 (2): 98–105. PMIDΒ 2720700.
  29. ↑ Muslimovic D, Post B, Speelman JD, Schmand B, de Haan RJ (June 2008). “Determinants of disability and quality of life in mild to moderate Parkinson disease”. Neurology. 70 (23): 2241–7. doi:10.1212/01.wnl.0000313835.33830.80. PMIDΒ 18519873.
  30. ↑ Svenningsson P, Westman E, Ballard C, Aarsland D (August 2012). “Cognitive impairment in patients with Parkinson’s disease: diagnosis, biomarkers, and treatment”. Lancet Neurol. 11 (8): 697–707. doi:10.1016/S1474-4422(12)70152-7. PMIDΒ 22814541.
  31. ↑ Muslimovic D, Post B, Speelman JD, Schmand B (October 2005). “Cognitive profile of patients with newly diagnosed Parkinson disease”. Neurology. 65 (8): 1239–45. doi:10.1212/01.wnl.0000180516.69442.95. PMIDΒ 16247051.
  32. ↑ Levin BE, Llabre MM, Reisman S, Weiner WJ, Sanchez-Ramos J, Singer C, Brown MC (March 1991). “Visuospatial impairment in Parkinson’s disease”. Neurology. 41 (3): 365–9. PMIDΒ 2006002.
  33. ↑ Stern Y, Richards M, Sano M, Mayeux R (October 1993). “Comparison of cognitive changes in patients with Alzheimer’s and Parkinson’s disease”. Arch. Neurol. 50 (10): 1040–5. PMIDΒ 8215961.
  34. ↑ Emre M, Aarsland D, Brown R, Burn DJ, Duyckaerts C, Mizuno Y, Broe GA, Cummings J, Dickson DW, Gauthier S, Goldman J, Goetz C, Korczyn A, Lees A, Levy R, Litvan I, McKeith I, Olanow W, Poewe W, Quinn N, Sampaio C, Tolosa E, Dubois B (September 2007). “Clinical diagnostic criteria for dementia associated with Parkinson’s disease”. Mov. Disord. 22 (12): 1689–707, quiz 1837. doi:10.1002/mds.21507. PMIDΒ 17542011.
  35. ↑ Hobson P, Meara J (September 2004). “Risk and incidence of dementia in a cohort of older subjects with Parkinson’s disease in the United Kingdom”. Mov. Disord. 19 (9): 1043–9. doi:10.1002/mds.20216. PMIDΒ 15372593.
  36. ↑ Aarsland D, Andersen K, Larsen JP, Lolk A, Nielsen H, Kragh-SΓΈrensen P (March 2001). “Risk of dementia in Parkinson’s disease: a community-based, prospective study”. Neurology. 56 (6): 730–6. PMIDΒ 11274306.
  37. ↑ Aarsland D, Bronnick K, Williams-Gray C, Weintraub D, Marder K, Kulisevsky J, Burn D, Barone P, Pagonabarraga J, Allcock L, Santangelo G, Foltynie T, Janvin C, Larsen JP, Barker RA, Emre M (September 2010). “Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis”. Neurology. 75 (12): 1062–9. doi:10.1212/WNL.0b013e3181f39d0e. PMCΒ 2942065. PMIDΒ 20855849.
  38. ↑ Emre M (August 2004). “Dementia in Parkinson’s disease: cause and treatment”. Curr. Opin. Neurol. 17 (4): 399–404. PMIDΒ 15247534.
  39. ↑ “Hallucinations in Parkinson’s disease. prevalence, phenomenology and risk factors. Fenelon G* mahieux F, huon R, Ziegler M. Brain 2000;123:733-745”. Am. J. Ophthalmol. 130 (2): 261–2. August 2000. PMIDΒ 11004314.
  40. ↑ Sanchez-Ramos JR, Ortoll R, Paulson GW (December 1996). “Visual hallucinations associated with Parkinson disease”. Arch. Neurol. 53 (12): 1265–8. PMIDΒ 8970453.
  41. ↑ Lee AH, Weintraub D (June 2012). “Psychosis in Parkinson’s disease without dementia: common and comorbid with other non-motor symptoms”. Mov. Disord. 27 (7): 858–63. doi:10.1002/mds.25003. PMCΒ 3511789. PMIDΒ 22674352.
  42. ↑ Cummings JL (July 1991). “Behavioral complications of drug treatment of Parkinson’s disease”. J Am Geriatr Soc. 39 (7): 708–16. PMIDΒ 2061539.
  43. ↑ Goetz CG, Wuu J, Curgian LM, Leurgans S (January 2005). “Hallucinations and sleep disorders in PD: six-year prospective longitudinal study”. Neurology. 64 (1): 81–6. doi:10.1212/01.WNL.0000148479.10865.FE. PMIDΒ 15642908.
  44. ↑ Friedman JH (May 1985). “‘Drug holidays’ in the treatment of Parkinson’s disease. A brief review”. Arch. Intern. Med. 145 (5): 913–5. PMIDΒ 3888135.
  45. ↑ 45.0 45.1 Aarsland D, Larsen JP, Lim NG, Janvin C, Karlsen K, Tandberg E, Cummings JL (October 1999). “Range of neuropsychiatric disturbances in patients with Parkinson’s disease”. J. Neurol. Neurosurg. Psychiatry. 67 (4): 492–6. PMCΒ 1736593. PMIDΒ 10486397.
  46. ↑ Ravina B, Camicioli R, Como PG, Marsh L, Jankovic J, Weintraub D, Elm J (July 2007). “The impact of depressive symptoms in early Parkinson disease”. Neurology. 69 (4): 342–7. doi:10.1212/01.wnl.0000268695.63392.10. PMCΒ 2031220. PMIDΒ 17581943.
  47. ↑ Tandberg E, Larsen JP, Aarsland D, Cummings JL (February 1996). “The occurrence of depression in Parkinson’s disease. A community-based study”. Arch. Neurol. 53 (2): 175–9. PMIDΒ 8639068.
  48. ↑ Gotham AM, Brown RG, Marsden CD (April 1986). “Depression in Parkinson’s disease: a quantitative and qualitative analysis”. J. Neurol. Neurosurg. Psychiatry. 49 (4): 381–9. PMCΒ 1028762. PMIDΒ 3701347.
  49. ↑ Broen MP, Narayen NE, Kuijf ML, Dissanayaka NN, Leentjens AF (August 2016). “Prevalence of anxiety in Parkinson’s disease: A systematic review and meta-analysis”. Mov. Disord. 31 (8): 1125–33. doi:10.1002/mds.26643. PMIDΒ 27125963.
  50. ↑ Wee N, Kandiah N, Acharyya S, Chander RJ, Ng A, Au WL, Tan LC (February 2016). “Depression and anxiety are co-morbid but dissociable in mild Parkinson’s disease: A prospective longitudinal study of patterns and predictors”. Parkinsonism Relat. Disord. 23: 50–6. doi:10.1016/j.parkreldis.2015.12.001. PMIDΒ 26711668.
  51. ↑ Reijnders JS, Scholtissen B, Weber WE, Aalten P, Verhey FR, Leentjens AF (October 2010). “Neuroanatomical correlates of apathy in Parkinson’s disease: A magnetic resonance imaging study using voxel-based morphometry”. Mov. Disord. 25 (14): 2318–25. doi:10.1002/mds.23268. PMIDΒ 20669264.
  52. ↑ Robert G, Le Jeune F, Lozachmeur C, Drapier S, Dondaine T, PΓ©ron J, Travers D, Sauleau P, Millet B, VΓ©rin M, Drapier D (September 2012). “Apathy in patients with Parkinson disease without dementia or depression: a PET study”. Neurology. 79 (11): 1155–60. doi:10.1212/WNL.0b013e3182698c75. PMIDΒ 22895582.
  53. ↑ 53.0 53.1 Tandberg E, Larsen JP, Karlsen K (November 1998). “A community-based study of sleep disorders in patients with Parkinson’s disease”. Mov. Disord. 13 (6): 895–9. doi:10.1002/mds.870130606. PMIDΒ 9827612.
  54. ↑ 54.0 54.1 Oerlemans WG, de Weerd AW (March 2002). “The prevalence of sleep disorders in patients with Parkinson’s disease. A self-reported, community-based survey”. Sleep Med. 3 (2): 147–9. PMIDΒ 14592234.
  55. ↑ 55.0 55.1 Gjerstad MD, Wentzel-Larsen T, Aarsland D, Larsen JP (May 2007). “Insomnia in Parkinson’s disease: frequency and progression over time”. J. Neurol. Neurosurg. Psychiatry. 78 (5): 476–9. doi:10.1136/jnnp.2006.100370. PMCΒ 2117851. PMIDΒ 17098844.
  56. ↑ Kumar S, Bhatia M, Behari M (July 2002). “Sleep disorders in Parkinson’s disease”. Mov. Disord. 17 (4): 775–81. doi:10.1002/mds.10167. PMIDΒ 12210875.
  57. ↑ Lees AJ, Blackburn NA, Campbell VL (December 1988). “The nighttime problems of Parkinson’s disease”. Clin Neuropharmacol. 11 (6): 512–9. PMIDΒ 3233589.
  58. ↑ Schrempf W, Brandt MD, Storch A, Reichmann H (2014). “Sleep disorders in Parkinson’s disease”. J Parkinsons Dis. 4 (2): 211–21. doi:10.3233/JPD-130301. PMIDΒ 24796235.
  59. ↑ Askenasy JJ, Yahr MD (September 1990). “Parkinsonian tremor loses its alternating aspect during non-REM sleep and is inhibited by REM sleep”. J. Neurol. Neurosurg. Psychiatry. 53 (9): 749–53. PMCΒ 1014251. PMIDΒ 2246656.
  60. ↑ Sixel-DΓΆring F, Trautmann E, Mollenhauer B, Trenkwalder C (September 2011). “Associated factors for REM sleep behavior disorder in Parkinson disease”. Neurology. 77 (11): 1048–54. doi:10.1212/WNL.0b013e31822e560e. PMIDΒ 21832215.
  61. ↑ Schenck CH, Mahowald MW (March 2002). “REM sleep behavior disorder: clinical, developmental, and neuroscience perspectives 16 years after its formal identification in SLEEP”. Sleep. 25 (2): 120–38. PMIDΒ 11902423.
  62. ↑ van Hilten JJ, Weggeman M, van der Velde EA, Kerkhof GA, van Dijk JG, Roos RA (1993). “Sleep, excessive daytime sleepiness and fatigue in Parkinson’s disease”. J Neural Transm Park Dis Dement Sect. 5 (3): 235–44. PMIDΒ 8369103.
  63. ↑ 63.0 63.1 Friedman J, Friedman H (October 1993). “Fatigue in Parkinson’s disease”. Neurology. 43 (10): 2016–8. PMIDΒ 8413960.
  64. ↑ 64.0 64.1 Karlsen K, Larsen JP, Tandberg E, JΓΈrgensen K (March 1999). “Fatigue in patients with Parkinson’s disease”. Mov. Disord. 14 (2): 237–41. PMIDΒ 10091615.
  65. ↑ Alves G, Wentzel-Larsen T, Larsen JP (November 2004). “Is fatigue an independent and persistent symptom in patients with Parkinson disease?”. Neurology. 63 (10): 1908–11. PMIDΒ 15557510.
  66. ↑ Tissingh G, Berendse HW, Bergmans P, DeWaard R, Drukarch B, Stoof JC, Wolters EC (January 2001). “Loss of olfaction in de novo and treated Parkinson’s disease: possible implications for early diagnosis”. Mov. Disord. 16 (1): 41–6. PMIDΒ 11215591.
  67. ↑ Ponsen MM, Stoffers D, Booij J, van Eck-Smit BL, Wolters E, Berendse HW (August 2004). “Idiopathic hyposmia as a preclinical sign of Parkinson’s disease”. Ann. Neurol. 56 (2): 173–81. doi:10.1002/ana.20160. PMIDΒ 15293269. Vancouver style error: initials (help)
  68. ↑ Ross GW, Petrovitch H, Abbott RD, Tanner CM, Popper J, Masaki K, Launer L, White LR (February 2008). “Association of olfactory dysfunction with risk for future Parkinson’s disease”. Ann. Neurol. 63 (2): 167–73. doi:10.1002/ana.21291. PMIDΒ 18067173.
  69. ↑ Goetz CG, Tanner CM, Levy M, Wilson RS, Garron DC (1986). “Pain in Parkinson’s disease”. Mov. Disord. 1 (1): 45–9. doi:10.1002/mds.870010106. PMIDΒ 3504231.
  70. ↑ Hillen ME, Sage JI (November 1996). “Nonmotor fluctuations in patients with Parkinson’s disease”. Neurology. 47 (5): 1180–3. PMIDΒ 8909426.
  71. ↑ Ford B, Louis ED, Greene P, Fahn S (July 1996). “Oral and genital pain syndromes in Parkinson’s disease”. Mov. Disord. 11 (4): 421–6. doi:10.1002/mds.870110411. PMIDΒ 8813222.
  72. ↑ Verbaan D, Marinus J, Visser M, van Rooden SM, Stiggelbout AM, van Hilten JJ (July 2007). “Patient-reported autonomic symptoms in Parkinson disease”. Neurology. 69 (4): 333–41. doi:10.1212/01.wnl.0000266593.50534.e8. PMIDΒ 17646625.
  73. ↑ Asahina M, Vichayanrat E, Low DA, Iodice V, Mathias CJ (June 2013). “Autonomic dysfunction in parkinsonian disorders: assessment and pathophysiology”. J. Neurol. Neurosurg. Psychiatry. 84 (6): 674–80. doi:10.1136/jnnp-2012-303135. PMIDΒ 22942216.
  74. ↑ Lemack GE, Dewey RB, Roehrborn CG, O’Suilleabhain PE, Zimmern PE (August 2000). “Questionnaire-based assessment of bladder dysfunction in patients with mild to moderate Parkinson’s disease”. Urology. 56 (2): 250–4. PMIDΒ 10925088.
  75. ↑ Araki I, Kitahara M, Oida T, Kuno S (November 2000). “Voiding dysfunction and Parkinson’s disease: urodynamic abnormalities and urinary symptoms”. J. Urol. 164 (5): 1640–3. PMIDΒ 11025724.
  76. ↑ Koller WC, Vetere-Overfield B, Williamson A, Busenbark K, Nash J, Parrish D (October 1990). “Sexual dysfunction in Parkinson’s disease”. Clin Neuropharmacol. 13 (5): 461–3. PMIDΒ 2272026.
  77. ↑ Singer C, Weiner WJ, Sanchez-Ramos JR (1992). “Autonomic dysfunction in men with Parkinson’s disease”. Eur. Neurol. 32 (3): 134–40. doi:10.1159/000116810. PMIDΒ 1592069.

Editor-In-Chief:
C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Fahimeh Shojaei, M.D.